Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone.

The genotype of CYP2D6 significantly influences the plasma concentration of risperidone and may subsequently influence the adverse side-effects following risperidone treatment, while also exerting a slight influence on clinical outcomes.